Public Disclosures and Reported Celebrity Use
Public disclosures from celebrities and executives have drawn attention to off-label use of semaglutide-based drugs like Ozempic, which is approved for type 2 diabetes and chronic weight management. Elon Musk stated in a 2022 interview that he lost weight using Wegovy, a sister drug to Ozempic made by Novo Nordisk, and referenced the drug on social media. Musk's disclosure contributed to a surge in online searches and investor interest in Novo Nordisk and its competitors, including Eli Lilly and its tirzepatide drug Mounjaro, which is approved for weight management. These disclosures often occur during earnings calls, podcasts, or social media posts, and they can move stock prices and volume in the pharmaceutical sector. Musk's public comments on weight-loss drugs have been cited in financial and health reporting as a case study in celebrity influence on pharma stocks.
Other public figures have discussed weight-loss treatments in interviews and social media posts without naming specific drugs, making it difficult to confirm exact medication use. Companies such as Novo Nordisk and Eli Lilly do not disclose individual patient data, including celebrity patients, due to privacy regulations. The U.S. Food and Drug Administration (FDA) has noted that off-label use of Ozempic for weight loss is common, but the agency does not track or publicize individual prescribing patterns. Investors and analysts monitor public statements by celebrities and executives for signals that may affect demand forecasts for GLP-1 receptor agonists. SEC filings and company disclosures provide additional context on how pharmaceutical companies report risks related to drug demand and public perception.
Market Impact and Financial Data
Novo Nordisk's market capitalization rose sharply in 2023 and 2024 as demand for Ozempic and Wegovy exceeded supply, with the company becoming one of the most valuable in Europe. Eli Lilly's market value also increased significantly as its weight-loss drug Mounjaro and experimental drug tirzepatide faced high demand. The global GLP-1 receptor agonist market is projected to reach over $100 billion in annual sales by the end of the decade, according to analyst estimates from firms such as Morgan Stanley and Goldman Sachs. Celebrity mentions and public disclosures have been cited in financial research as factors that can accelerate demand spikes and affect pricing strategies for these drugs.
Insurance coverage and out-of-pocket costs for Ozempic and similar drugs remain a key financial topic for both consumers and investors. U.S. private insurers and government programs such as Medicare and Medicaid have updated policies on coverage for GLP-1 drugs, affecting market access and revenue projections. Novo Nordisk and Eli Lilly have faced supply constraints and pricing scrutiny, leading to discussions about biosimilars and compounding pharmacies. Forbes reporting on Ozempic costs and insurance highlights the financial barriers that influence public perception and celebrity disclosures about these treatments.
Regulatory and Scientific Context
The FDA approved Ozempic (semaglutide) for type 2 diabetes in 2017 and approved a higher-dose version, Wegovy, for chronic weight management in 2021. The FDA has issued warnings about compounding pharmacies that prepare semaglutide without approved formulations, citing safety and quality risks. Public figures using these drugs often emphasize the importance of medical supervision, and the FDA advises patients to use only FDA-approved versions of the drug.